|
Video: What is a Stock Split?
|
|
Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Co.'s most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. Co. is evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2 clinical trial; and RLYB116, a subcutaneously administered inhibitor of complement factor 5. According to our Rallybio stock split history records, Rallybio has had 0 splits. | |
|
Rallybio (RLYB) has 0 splits in our Rallybio stock split history database.
Looking at the Rallybio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Rallybio shares, starting with a $10,000 purchase of RLYB, presented on a split-history-adjusted basis factoring in the complete Rallybio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/30/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$17.00 |
|
End price/share: |
$1.70 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-90.00% |
|
Average Annual Total Return: |
-56.81% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,000.12 |
|
Years: |
2.74 |
|
|
|
|
|